Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,366 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Chemotherapy after PD-1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics.
Calabretta E, Guidetti A, Ricci F, Di Trani M, Monfrini C, Magagnoli M, Bramanti S, Maspero D, Morello L, Merli M, Di Rocco A, Graudenzi A, Derenzini E, Antoniotti M, Rossi D, Corradini P, Santoro A, Carlo-Stella C. Calabretta E, et al. Among authors: ricci f. Br J Haematol. 2022 Jul;198(1):82-92. doi: 10.1111/bjh.18183. Epub 2022 Apr 25. Br J Haematol. 2022. PMID: 35468225 Free PMC article.
Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers.
Carlo-Stella C, Ricci F, Dalto S, Mazza R, Malagola M, Patriarca F, Viviani S, Russo D, Giordano L, Castagna L, Corradini P, Santoro A. Carlo-Stella C, et al. Among authors: ricci f. Oncologist. 2015 Mar;20(3):323-8. doi: 10.1634/theoncologist.2014-0420. Epub 2015 Feb 10. Oncologist. 2015. PMID: 25669663 Free PMC article.
Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma.
Santoro A, Mazza R, Pulsoni A, Re A, Bonfichi M, Zilioli VR, Zanni M, Merli F, Anastasia A, Luminari S, Annechini G, Gotti M, Peli A, Liberati AM, Di Renzo N, Castagna L, Giordano L, Ricci F, Carlo-Stella C. Santoro A, et al. Among authors: ricci f. Blood Adv. 2020 Jan 14;4(1):136-140. doi: 10.1182/bloodadvances.2019000984. Blood Adv. 2020. PMID: 31935284 Free PMC article. Clinical Trial.
Methodological framework for radiomics applications in Hodgkin's lymphoma.
Sollini M, Kirienko M, Cavinato L, Ricci F, Biroli M, Ieva F, Calderoni L, Tabacchi E, Nanni C, Zinzani PL, Fanti S, Guidetti A, Alessi A, Corradini P, Seregni E, Carlo-Stella C, Chiti A. Sollini M, et al. Among authors: ricci f. Eur J Hybrid Imaging. 2020 Jun 1;4(1):9. doi: 10.1186/s41824-020-00078-8. Eur J Hybrid Imaging. 2020. PMID: 34191173 Free PMC article.
Immune checkpoint inhibitors in combination with radiotherapy as salvage treatment for relapsed/refractory classical Hodgkin lymphoma: A retrospective analysis in 12 patients.
Lucchini E, Rusconi C, Levis M, Ricci F, Santoro A, Ricardi U, Volpetti S, Matrone F, di Russo A, Caizzi M, Schiattarella A, Zaja F. Lucchini E, et al. Among authors: ricci f. Hematol Rep. 2021 Jun 9;13(2):9080. doi: 10.4081/hr.2021.9080. eCollection 2021 Jun 9. Hematol Rep. 2021. PMID: 34221295 Free PMC article.
Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome.
Dodero A, Guidetti A, Marino F, Tucci A, Barretta F, Re A, Balzarotti M, Carniti C, Monfrini C, Chiappella A, Cabras A, Facchetti F, Pennisi M, Rahal D, Monti V, Devizzi L, Miceli R, Cocito F, Farina L, Ricci F, Rossi G, Carlo-Stella C, Corradini P. Dodero A, et al. Among authors: ricci f. Haematologica. 2022 May 1;107(5):1153-1162. doi: 10.3324/haematol.2021.278638. Haematologica. 2022. PMID: 34289655 Free PMC article.
Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi.
Santoro A, Mazza R, Spina M, Califano C, Specchia G, Carella M, Consoli U, Palombi F, Musso M, Pulsoni A, Kovalchuk S, Bonfichi M, Ricci F, Fabbri A, Liberati AM, Rodari M, Giordano L, Chimienti E, Balzarotti M, Sorasio R, Gallamini A, Ghiggi C, Ciammella P, Ricardi U, Chauvie S, Carlo-Stella C, Merli F. Santoro A, et al. Among authors: ricci f. Ann Hematol. 2021 Oct;100(10):2547-2556. doi: 10.1007/s00277-021-04604-x. Epub 2021 Jul 30. Ann Hematol. 2021. PMID: 34327561 Clinical Trial.
Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab.
De Filippi R, Morabito F, Santoro A, Tripepi G, D'Alò F, Rigacci L, Ricci F, Morelli E, Zinzani PL, Pinto A. De Filippi R, et al. Among authors: ricci f. J Transl Med. 2021 Dec 1;19(1):489. doi: 10.1186/s12967-021-03134-4. J Transl Med. 2021. PMID: 34852840 Free PMC article.
Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.
Gotti M, Sciarra R, Pulsoni A, Merli F, Luminari S, Zerbi C, Trentin L, Re A, Rusconi C, Viviani S, Rossi A, Cocito F, Botto B, Meli E, Pinto A, Dogliotti I, Gini G, Puccini B, Ricci F, Nassi L, Fabbri A, Liberati AM, Merli M, Filippi AR, Bonfichi M, Zoboli V, Tartaglia G, Annechini G, D'Elia GM, Del Giudice I, Alvarez I, Visentin A, Pravato S, Dalceggio D, Pagani C, Ferrari S, Cristinelli C, Lazic T, Ferretti VV, Ricardi U, Arcaini L. Gotti M, et al. Among authors: ricci f. Hemasphere. 2023 Apr 4;7(4):e837. doi: 10.1097/HS9.0000000000000837. eCollection 2023 Apr. Hemasphere. 2023. PMID: 37034003 Free PMC article.
1,366 results